Thursday, February 2, 2023
Google search engine
HomeMarketResultsCantor Fitzgerald Reiterates Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Cantor Fitzgerald Reiterates Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA)


Taysha Gene Therapies (NASDAQ:TSHAGet Rating)‘s inventory had its “chubby” ranking reiterated by equities researchers at Cantor Fitzgerald in a analysis report issued to shoppers and buyers on Wednesday, PriceTargets.com stories.

A number of different analysts have additionally lately commented on TSHA. Robert W. Baird dropped their worth goal on Taysha Gene Therapies from $26.00 to $21.00 and set an “outperform” ranking for the corporate in a analysis report on Wednesday, October twenty sixth. Needham & Firm LLC lowered their worth goal on Taysha Gene Therapies from $18.00 to $16.00 and set a “purchase” ranking on the inventory in a analysis notice on Tuesday, November eighth. Wells Fargo & Firm lowered their worth goal on Taysha Gene Therapies from $20.00 to $14.00 in a analysis notice on Monday, November 14th. JMP Securities decreased their worth goal on Taysha Gene Therapies from $22.00 to $20.00 and set a “market outperform” ranking on the inventory in a analysis notice on Thursday, November tenth. Lastly, BTIG Analysis decreased their worth goal on Taysha Gene Therapies from $25.00 to $15.00 in a analysis notice on Thursday, November tenth. One analyst has rated the inventory with a maintain ranking and eleven have assigned a purchase ranking to the corporate’s inventory. In keeping with information from MarketBeat.com, the inventory at the moment has a consensus ranking of “Reasonable Purchase” and a median goal worth of $16.46.

Taysha Gene Therapies Inventory Up 4.5 %

Shares of TSHA opened at $2.08 on Wednesday. The corporate has a debt-to-equity ratio of three.40, a fast ratio of 1.30 and a present ratio of 1.30. Taysha Gene Therapies has a one yr low of $1.35 and a one yr excessive of $13.31. The inventory has a market capitalization of $129.88 million, a price-to-earnings ratio of -0.51 and a beta of 1.45. The inventory has a 50 day transferring common worth of $2.07 and a 200 day transferring common worth of $2.93.

Taysha Gene Therapies (NASDAQ:TSHAGet Rating) final issued its quarterly earnings outcomes on Tuesday, November eighth. The corporate reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.25. Equities analysis analysts forecast that Taysha Gene Therapies will submit -3.07 earnings per share for the present fiscal yr.

Insiders Place Their Bets

In associated information, Director Paul B. Manning bought 1,500,000 shares of the enterprise’s inventory in a transaction on Monday, October thirty first. The shares had been purchased at a median worth of $2.00 per share, for a complete transaction of $3,000,000.00. Following the acquisition, the director now immediately owns 1,642,202 shares within the firm, valued at $3,284,404. The acquisition was disclosed in a authorized submitting with the Securities & Change Fee, which is accessible by means of the SEC website. 42.40% of the inventory is owned by firm insiders.

Institutional Traders Weigh In On Taysha Gene Therapies

A number of giant buyers have lately purchased and bought shares of the inventory. Swiss Nationwide Financial institution elevated its holdings in Taysha Gene Therapies by 9.3% throughout the 1st quarter. Swiss Nationwide Financial institution now owns 41,000 shares of the corporate’s inventory value $267,000 after buying a further 3,500 shares throughout the interval. Occudo Quantitative Methods LP elevated its holdings in shares of Taysha Gene Therapies by 17.9% within the 2nd quarter. Occudo Quantitative Methods LP now owns 31,030 shares of the corporate’s inventory valued at $115,000 after buying a further 4,702 shares over the past quarter. Quantum Non-public Wealth LLC elevated its holdings in shares of Taysha Gene Therapies by 3.8% within the 2nd quarter. Quantum Non-public Wealth LLC now owns 157,774 shares of the corporate’s inventory valued at $586,000 after buying a further 5,800 shares over the past quarter. Sargent Funding Group LLC elevated its holdings in shares of Taysha Gene Therapies by 66.9% within the 2nd quarter. Sargent Funding Group LLC now owns 17,788 shares of the corporate’s inventory valued at $66,000 after buying a further 7,132 shares over the past quarter. Lastly, Financial institution of America Corp DE elevated its holdings in shares of Taysha Gene Therapies by 15.8% within the 1st quarter. Financial institution of America Corp DE now owns 71,358 shares of the corporate’s inventory valued at $465,000 after buying a further 9,712 shares over the past quarter. Hedge funds and different institutional buyers personal 45.12% of the corporate’s inventory.

Taysha Gene Therapies Firm Profile

(Get Rating)

Taysha Gene Therapies, Inc, a gene remedy firm, focuses on growing and commercializing adeno-associated virus-based gene therapies for the therapy of monogenic ailments of the central nervous system. It primarily develops TSHA-120 for the therapy of large axonal neuropathy; TSHA-102 for the therapy of Rett syndrome; TSHA-121 for the therapy of CLN1 illness; TSHA-118 for the therapy of CLN1 illness; TSHA-105 foe the therapy of for SLC13A5 Deficiency; and TSHA-101 for the therapy of GM2 gangliosidosis.

Learn Extra

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat in an effort to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Taysha Gene Therapies, you may need to hear this.

MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they suggest to their shoppers each day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Taysha Gene Therapies wasn’t on the listing.

Whereas Taysha Gene Therapies at the moment has a “Reasonable Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments